

Supplementary materials

A Novel Aminomethacrylate-Based Copolymer for Solubility Enhancement—From Radical Polymer Synthesis to Manufacture and Characterization of Amorphous Solid Dispersions

Fabian-Pascal Schmied ^{1,2}, Alexander Bernhardt ², Christian Moers ², Christian Meier ³, Thomas Endres ² and Sandra Klein ^{1,*}

¹ University of Greifswald, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Felix-Hausdorff-Straße 3, 17489 Greifswald, Germany; fabian-pascal.schmied@stud.uni-greifswald.de (F.-P.S.); sandra.klein@uni-greifswald.de (S.K.)

² Evonik Operations GmbH, Research, Development & Innovation, Kirschenallee, 64293 Darmstadt, Germany; fabian-pascal.schmied@evonik.com (F.-P.S.); alexander.bernhardt@evonik.com (A.B.); christian.moers@evonik.com (C.M.); thomas.endres@evonik.com (T.E.)

³ Evonik Operations GmbH, Research, Development & Innovation, Rodenbacher Chaussee 4, 63457 Hanau, Germany; christian.meier@evonik.com (C.M.)

* Correspondence: sandra.klein@uni-greifswald.de; Tel.: +49-3834-420-4897




Figure S1. Results from isothermal TGA of ModE copolymers at 150 °C (a) and 165 °C (b).




Figure S2. DSC thermograms of celecoxib, ModE copolymers, EPO and the corresponding ASDs (a), and celecoxib and other marketed (co-)polymers used in the study, and the corresponding ASDs (b).




Figure S3. DSC thermograms of efavirenz, ModE copolymers, EPO and the corresponding ASDs (a), and efavirenz and other marketed (co-)polymers used in the study, and the corresponding ASDs (b).




Figure S4. DSC thermograms of fenofibrate, ModE copolymers, EPO and the corresponding ASDs (a), and fenofibrate and other marketed (co-)polymers used in the study, and the corresponding ASDs (b).




Figure S5. DSC thermograms (after three months of storage at 30 °C/65% RH) of celecoxib, Mode copolymers, EPO and the corresponding ASDs (a), and celecoxib and other marketed (co-)polymers used in the study, and the corresponding ASDs (b);.






Figure S6. DSC thermograms (after three months of storage at 30 $^{\circ}C$ /65% RH) of efavirenz, Mode copolymers, EPO and the corresponding ASDs (a), and efavirenz and other marketed (co-)polymers used in the study, and the corresponding ASDs (b).



(a)



(b)

Figure S7. DSC thermograms (after three months of storage at 30 °C/65% RH) of fenofibrate, ModE copolymers, EPO and the corresponding ASDs (a), and fenofibrate and other marketed (co-)polymers used in the study, and the corresponding ASDs (b).